直肠癌新辅助化疗前后血清 VEGF 与 VEGFR -2 的变化及临床意义 |
| |
引用本文: | 连文,陈转鹏,杨平,廖述文,孙政,张伟健,曾山崎,曹杰.直肠癌新辅助化疗前后血清 VEGF 与 VEGFR -2 的变化及临床意义[J].河北中西医结合杂志,2014(3):235-237. |
| |
作者姓名: | 连文 陈转鹏 杨平 廖述文 孙政 张伟健 曾山崎 曹杰 |
| |
作者单位: | 广州医科大学附属广州市第一人民医院,广东广州510180 |
| |
基金项目: | [基金项目]广东省医学科研基金项目(A2005543);广东省科技计划项目(20108060900016) |
| |
摘 要: | 目的探讨直肠癌患者新辅助化疗前后血清血管内皮生长因子(VEGF)及血管内皮细胞生长因子受体2(VEGFR-2)水平的变化及临床意义。方法应用ELISA法检测45例直肠癌患者(化疗组)新辅助化疗前后血清VEGF与VEGFR-2的表达水平,并与45例正常健康人(对照组)作比较。结果化疗组新辅助化疗前血清VEGF、VEGFR-2水平均明显高于对照组(P均〈0.01)。新辅助化疗8周后,完全缓解及部分缓解组VEGF、VEGFR-2表达水平均较化疗前明显降低(P均〈0.05),降低程度明显高于稳定组(P均〈0.01);稳定组化疗后VEGFR、VEGF-2较化疗前显著降低(P均〈0.05);进展组化疗后VEGF、VEGFR-2水平均较化疗前显著升高(P均〈0.05)。化疗前VEGFR水平与VEGF-2表达呈正相关关系(P〈0.01)。结论直肠癌患者血清中VEGFR、VEGF-2均高表达。测定直肠癌患者新辅助化疗前后血清VEGFR、VEGF-2水平的变化有助于临床判断化疗效果及肿瘤进程。
|
关 键 词: | 直肠癌 新辅助化疗 血清血管内皮生长因子 血管内皮细胞生长因子受体2 |
Clinical significance of the serum levels of VEGF and VEGFR -2 in patients with rectal cancer before and after neoadjuvant chemotherapy |
| |
Authors: | Lian Wen Chen Zhuanpeng Yang Ping Liao Shuwen Sun Zheng Zhang Weijian Zeng Shanqi Cao Jie |
| |
Institution: | (Guangzhou First People's Hospital of Guangzhou Medical University, Guangzhou 510180, Guangdong, China) |
| |
Abstract: | Objective It is to approach the clinical significance of the serum level changes of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor - 2 ( VEGFR - 2) in patients with rectal cancer before and after neoadjuvant chemotherapy. Methods The serum levels of VEGF and VEGFR - 2 of 45 cases with colon carcinoma patients were detected by ELISA and which were compared with those in 45 healthy people. Results The serum levels of VEGF and VEGFR- 2 in colon carcinoma patients before neoadjuvant chemotherapy were significantly higher than those in the healthy people (P 〈0.01 ). The serum levels in complete remission and partial remission patients in eight-weeks post-chemotherapy were significantly lower than those in pre-chemotherapy ( P 〈 0.05 ) , and lower levels were obviously higher than the stable group ( P 〈 0.01 ). The VEGF, VEGFR - 2 levels in the stable treatment patients were also lower than that of before neoadju- vant chemotherapy ( P 〈 0.05 ). The serum levels in the progression group were markedly higher than those of before treatment ( P 〈 0.05 ). There was positive correlation in serum levels of VEGF and VEGFR - 2 before chemotherapy ( P 〈 0. 01 ). Con- clusion The serum levels of VEGF and VEGFR - 2 in rectal cancer are high expression. The determination of VEGFR and VEGFR - 2 levels changes in patients with rectal cancer before and after neoadjuvant chemotherapy is helpful to determine the effecl of chemotherapy and the progression of tumor. |
| |
Keywords: | rectal cancer neoadjuvant chemotherapy vascular endothelial growth factor vascular endothelial growthfactor receptor - 2 |
本文献已被 维普 等数据库收录! |